莫西沙星治疗肝硬化并发原发性腹膜炎的疗效观察

The Observation on Efficacy of Moxifloxacin in Treating Primary Peritonitis in Patients with Cirrhosis

目的：观察莫西沙星治疗肝硬化并发原发性腹膜炎的疗效。方法：98例病例随机分成治疗组（51例）和对照组（47例），治疗组使用莫西沙星注射液400mg，静滴，1次／天；对照组使用头孢哌酮／舒巴坦钠2g＋左氧氟沙星注射液0．2g，静滴，2次／次，疗程7～10天。结果：治疗组总有效率为90．2％，明显高于对照组72．3％（P〈0．05），并且能较快缓解患者感染的症状和体征，不良反应发生率仅为3．9％。结论：莫西沙星是治疗肝硬化并发原发性腹膜炎安全有效的药物。

Objective：To evaluate the efficacy of moxifloxacin in treating primary peritonitis in patients with cirrhosis. Methods： Nitety-eight patients were randomised to either moxifloxacin group（51 cases）or control group（47 cases）. The moxifloxacin group received a single intravenous infusion of moxifloxacin 400 mg, qd. The control group received intravenous infusion of cefoperazone/sulbactam, 2g bid with Levofloxacin 0.2g, bids and the course of treatment is 7-10 days. Results;The total effective rate of the moxifloxacin（90. 2%）is obviously higher than that of the control group （72.30% ）（P〈0.05）, and the objective sign and symptom in moxifloxacin group are alleviated more rapidly. The drugrelated adverse events of moxifloxacin is only 3.9 %. Conclusion： Moxifloxacin is safe and effective drug for treating primary peritonitis in patients with cirrhosis.